Compare Mesoblast Limited (MESO) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Msci Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Msci Inc trades at $562.19 (market cap $40.38B). The key difference: Msci Inc is far larger — about 23.1× Mesoblast Limited's market cap, and Msci Inc pays a 1.48% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Msci Inc for 82 Days on average.
| MESO | MSCI | |
|---|---|---|
Market Cap | $1.75B | $40.38B |
Volume | 239,027 | 414,140 |
Sector | Health | Financials |
52-Week High | $20.96 | $643.83 |
52-Week Low | $13.19 | $511.84 |
Typical Hold Time | 14 Days | 82 Days |
Enterprise Value | $1.83B | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
MSCI trades at $555.38, up 0.08% on the day, with a neutral technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed slightly. Analyst sentiment is bullish with a 74% buy rating and a $701.71 consensus price target, suggesting significant upside. The company maintains robust cash flow from operations at $1.59B in 2025.
Outlook remains positive due to high profitability and analyst confidence, but risks include elevated valuation multiples and high long-term debt of $4.51B. The upcoming Q3 2026 earnings call on October 20, 2026, will be a key catalyst. Investors should weigh the strong growth trajectory against debt levels and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
